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Translational potential of human embryonic and induced pluripotent 
stem cells for myocardial repair: Insights from experimental models 
Chi-Wing Kong1; Fadi G. Akar2; Ronald A. Li1,2 
1Stem Cell & Regenerative Medicine Program, Heart, Brain, Hormone & Healthy Aging Research Center, and Department of Medicine, University of Hong Kong, Hong Kong, China; 
2Center of Cardiovascular Research, Mount Sinai School of Medicine, New York, New York, USA 
Summary 
Heart diseases have been a major cause of death worldwide, including 
developed countries. Indeed, loss of non-regenerative, terminally differ-
entiated cardiomyocytes (CMs) due to aging or diseases is irreversible. 
Current therapeutic regimes are palliative in nature, and in the case of 
end-stage heart failure, transplantation remains the last resort. How-
ever, this option is significantly hampered by a severe shortage of donor 
cells and organs. Human embryonic stem cells (hESCs) can self-renew 
while maintaining their pluripotency to differentiate into all cell types. 
More recently, direct reprogramming of adult somatic cells to become 
pluripotent hES-like cells (a.k.a. induced pluripotent stem cells or iPSCs) 
has been achieved. The availability of hESCs and iPSCs, and their suc-
cessful differentiation into genuine human heart cells have enabled re-
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searchers to gain novel insights into the early development of the 
human heart as well as to pursue the revolutionary paradigm of heart 
regeneration. Here we review our current knowledge of hESC-/iPSC-de-
rived CMs in the context of two fundamental operating principles of 
CMs (i.e. electrophysiology and Ca2+-handling), the resultant limi-
tations and potential solutions in relation to their translation into clini-
cal (bioartificial pacemaker, myocardial repair) and other applications 
(e.g. as models for human heart disease and cardiotoxicity screening). 
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Heart disease and motivation for cell-based 
therapy 
The heart beats with a regular rhythm to pump blood throughout 
the body. These pumping actions require the highly coordinated 
efforts of different types of cardiomyocytes (CMs) such as atrial, 
ventricular and pacemaker cells. These different CMs differ in their 
cellular morphologies, structural and functional properties. Au-
tonomous rhythmic heart beats are modulated by sympathetic and 
parasympathetic means according to everyday needs. Normal 
rhythms originate in the sino-atrial (SA) node, a specialised car-
diac tissue consisting of only a few thousands pacemaker cells. The 
SA node generates spontaneous rhythmic action potentials which 
subsequently propagate (i.e. the processes of pacing and conduc-
tion, respectively) to induce coordinated muscle contractions of 
the atria and ventricles for effective blood pumping. Since termin-
ally-differentiated adult CMs lack the ability to regenerate, their 
malfunction or significant loss due to disease or aging can lead to 
lethal consequences such as heart failure and various lethal forms 
of arrhythmias. Heart transplantation for patients with end-stage 
heart failure is limited by the number of donor organs available; 
cell replacement therapy is a promising option for myocardial re-
pair but limited by the availability of transplantable human CMs 
(e.g. human fetal CMs) due to practical and ethical reasons. As a re-
sult, transplantation of non-cardiac cells such as skeletal muscle 
myoblasts (SkM) and smooth muscle cells have been sought as po-
tentially viable alternatives. However, the non-cardiac identity of 
these cell sources presented major limitations. For instance, the 
lack of electrical integration of SkM (conduction via gap junc-
tions) after their autologous transplantation into the myocardium 
has been shown to underlie the generation of malignant ventricu-
lar arrhythmias, which led to the premature termination of clinical 
trials involving this specific cell source (1). Moreover, it is now well 
established that although bone marrow stem cells improve cardiac 
functions of ischaemic patients by promoting angiogenesis (2), 
they lack the capacity to transdifferentiate into cardiac muscle for 
myocardiogenesis (3), limiting their utility for cardiac repairs. Re-
cently, adult cardiac resident stem cells have been explored as an 
autologous cell source. Here we will focus our discussion on 
human embryonic stem cells (hESC) and induced pluripotent 
stem cell (iPSC). 
Kong et al. Translational potential of human ESC and iPSC 
Human embryonic stem cells 
Upon fertilisation of an oocyte by sperm, the resultant zygote, 
which possesses the total potential (i.e. totipotency) to develop 
into all cell types including those necessary for embryonic devel-
opment (such as extra-embryonic tissues), will undergo several 
rounds of cell division to become a compact ball of totipotent cells 
known as the morula. As the morula continues to grow (∼4 days 
after fertilisation), its cells will migrate to form a more specialised 
hollow, fluid-filled structure known as the blastocyst consisting of 
an outer cell layer, the trophectoderm, and an inner cluster of cells 
collectively known as the inner cell mass (ICM). While the trop-
hectoderm is committed to developing into extra-embryonic 
structures for supporting fetal development, the ICM will give rise 
to the embryo. The ICM retains the ability to form any cell of the 
body except the placental tissues (i.e. pluripotency). Embryonic 
stem cells (ESCs) are isolated from the ICM for cultivation in vitro. 
ESCs possess the ability to remain undifferentiated and propagate 
indefinitely in culture while maintaining their normal karyotypes 
and pluripotency to differentiate into the derivatives of all three 
embryonic germ layers (i.e. endoderm, mesoderm and ectoderm) 
and their lineage derivatives, including brain, blood, pancreatic, 
heart and other muscle cells. Pluripotent mammalian ESC lines 
were first derived from rodent blastocysts over 20 years ago, revol-
utionising mouse genetics and leading to the generation of the first 
transgenic animal. The first successful isolation of human ESCs 
(hESCs) by Thomson et al in 1998 further sparked tremendous in-
ternational scientific interest: Since hESCs are immortal, they can 
potentially act as an unlimited ex vivo source of even non-dividing, 
terminally differentiated cells for transplantation and cell-based 
human therapies. Indeed, hESCs can self-renew while maintaining 
their pluripotency to differentiate into all cell types (4), including 
CMs (5–9).  
Induced pluripotent stem cells 
Although hESC-derived CMs (hESC-CMs) have been reported to 
improve cardiac function in several animal models of myocardial 
infarction (10, 11), numerous hurdles need to be overcome before 
their clinical applications. For instance, generation of patient-spe-
cific cells for autologous transplantation has been pursued to avoid 
immune rejection of the transplanted grafts. This can be accom-
plished by somatic cell nuclear transfer (SCNT) of a patient’s own 
nucleus to an enucleated donor oocyte to generate a cloned blasto-
cyst for the derivation of patient-specific ESCs. To date, the estab-
lishment of non-human primate “patient-specific” ESCs (12) and 
cloning of several animal species (13, 14) have been successfully 
achieved via SCNT; however, significant ethical concerns remain 
for the application of SCNT in human therapies. Alternatively, di-
rect reprogramming of adult somatic cells such as dermal fibrob-
lasts to become pluripotent hES-like cells (a.k.a. induced pluripo-
tent stem cells or iPSCs) has been recently reported, eliminating 
potential ethical concerns and making hES/iPS cell-based ther-
apies one step closer to reality. Forced expression of four pluripo-
tency genes (Oct3/4, Sox2 and either c-Myc and Klf4 for mouse 
and human or Lin28 and Nanog for human) (15–18) suffices to re-
program mouse and human fibroblasts into iPSCs. iPSCs have 
morphology, proliferation, feeder dependence, surface markers, 
gene expression, epigenetic status, formation of embryoid bodies 
in vitro, promoter activities, telomerase activities, and in vivo tera-
toma formation similar to hESCs. Technically, iPSCs are cultured 
under conditions virtually identical to those for hESCs (17, 18). 
Using the same cardiac differentiation protocol originally devel-
oped for hESCs, iPSCs can be similarly differentiated into CMs 
(17).  
Directed cardiac differentiation 
Previous studies using CMs derived from murine (m) and human 
ESCs have provided significant insights into the development of 
mammalian hearts. In vitro ESC differentiation requires an initial 
step of forming three-dimensional aggregates called embryoid 
bodies (EBs), which in turn can differentiate into a wide variety of 
specialised cell types including CMs. Once differentiated, CMs can 
be readily identified even by visual inspection as spontaneously-
contracting outgrowths (9). The cardiogenicity of ESCs is heavily 
influenced by conditions such as the EB size, media composition 
(e.g. the presence of fetal bovine serum, inducing agents and other 
growth and transcription factors), the particular ESC lines being 
investigated, the time and duration of differentiation. The devel-
opmental changes of mESC-derived CMs correlates with the 
length of time in culture, mimicking that seen in myocardial devel-
opment in vivo: primordial pacemaker-like and SA nodal pace-
maker (early), atrial (intermediate) and ventricular (late) CMs ap-
pear and predominate at different stages during cardiac differenti-
ation although a heterogenous population of all three CM types is 
almost always seen in mouse EBs. Terminal differentiation and 
derivation of specific CM types is an area of tremendous interests 
that requires further investigation. Morphologically, mESC-de-
rived nodal cells are non-striated, small and round whereas the at-
rial and ventricular counterparts show organised myofibrillar and 
sarcomeric structures found in mature cardiac muscle cells. Some 
nodal CMs lack the contractile apparatus (e.g. leading pacemaker 
cells in the SA node centre), and thus do not beat (without coup-
ling to muscle CMs) although they are electrically active; in 
contrast, mononucleated and rod-shaped striated atrial and ven-
tricular derivatives are normally quiescent but are capable of beat-
ing upon stimulation by electrical signals from nodal or neigh-
bouring CMs. Recently, several unique multipotent primordial 
cardiac progenitor populations have been identified (19–21). As an 
example, specification of human tripotent KDRlow/c-kitneg cardio-
vascular progenitors (CP) into CMs has been reported (19). Stage-
specific induction of hESCs with activin A, BMP4, bFGF, VEGF 
and DKK1 for driven mesodermal differentiation results in gener-
ation of a KDRlow/c-kitneg CP population which defines one of the 
earliest stages of human cardiac development. CP-containing “car-
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diospheres” derived from hESCs can efficiently differentiate into 
CMs in vitro (with >50%, as gauged by CTNT+ cells). Further 
modifications of this protocol enable the induction of a large CP 
population, allowing the generation of highly enriched CMs even 
without the need for cell sorting. When properly instructed, CP 
can also differentiate into smooth muscle and endothelial cells. 
Functional and structural properties of hESC- 
and iPSC-derived cardiomyocytes 
The functional and structural properties of hESC-CMs have been 
investigated by us and several laboratories. Human ESC-CMs ex-
press cardiac-specific transcription factors and structural proteins 
(5–9). Like the murine counterpart, hESC-CMs derived from in 
vitro differentiation were highly heterogenous consisting of a com-
bination of chamber-specific cell types. A directed differentiation 
protocol for deriving a particular chamber-specific type (e.g., the 
ventricular lineage), however, has not been established. Although 
all hESC lines are by definition pluripotent, we found that different 
lines have distinct cardiogenic potentials to become early ventricu-
lar-, atrial- and pacemaker-like derivatives as gauged by their sig-
nature action potential (AP) profiles. For instance, HES2 cells have 
a higher likelihood than H1 cells of differentiating into ventricu-
lar-like hESC-CMs (23) (Fig. 1). In the sections that follow, we 
will focus our discussion on electrophysiology and Ca2+-handling, 
two fundamental operating properties of CMs. 
Functional but immature Ca2+-handling of 
hESC-CMs 
During an action potential (AP) of adult CMs, Ca2+ entry into the cy-
tosol through sarcolemmal L-type Ca2+ (ICa,L) channels triggers the 
release of Ca2+ from the intracellular Ca2+ stores (a.k.a. sarcoplasmic 
reticulum or SR) via the ryanodine receptors (RyR). This process, the 
so-called Ca2+-induced Ca2+-release (CICR) (24), escalates the cyto-
solic Ca2+ ([Ca2+]i) to activate the contractile apparatus for contrac-
Figure 1: Action potentials (A, C) and pie 
graphs (B, D) showing the % distribution of 
chamber-specific CMs from HES2 and H1, 
respectively. Adapted from Moore et al. 2008. 
A 
B 
C 
D 
tion. For relaxation, elevated [Ca2+]i gets pumped back into the SR by 
the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and ex-
truded by the Na+-Ca2+ exchanger (NCX) to return to the resting 
[Ca2+]i level. Such a rise and subsequent decay of [Ca2+]i is known as 
Ca2+ transient. Both the contractile force (inotropic) and frequency 
(chronotropic) of CMs are dependent on the amplitude and kinetic 
properties of Ca2+ transients. In mature ventricular CMs, CICR is 
optimised by the presence of t-tubules, invaginations in the sarcol-
emmal membrane that concentrates ICa,L channels and brings them 
spatially closer to RyRs (25, 26). With a minimised Ca2+diffusion dis-
tance between ICa,L and RyRs, SR deep in ventricular CMs with large 
cross-sectional area can participate in CICR without significant time 
lags. This increased efficiency is demonstrated by a uniform increase 
in cytosolic Ca2+ across the transverse section of the cell (with simul-
taneous recruitment of all SRs). Such a uniform Ca2+ wave starkly 
contrasts the U-shaped Ca2+ wave propagation from the periphery 
to the center in a de-tubulated ventricular or atrial CM (that lacks 
t-tubules) (25). The U-shaped waves result from a time delay that is 
proportional to the diffusion distance squared in recruiting the Ca2+ 
stores at the cell centre (27). 
Given the central importance of CICR in cardiac excitation-
contraction (EC) coupling, proper Ca2+ handling properties of 
hESC/iPSC-CMs are therefore crucial for their successful func-
tional integration with the recipient heart after transplantation. In-
deed, abnormal Ca2+ handling, as in the case of heart failure, can 
even be arrhythmogenic (e.g. by causing delayed afterdepolar-
ization) (24). In murine (m) ESC-CMs, both the SR load and RyR 
are essential for regulating contractions even at very early devel-
opmental stages (28, 29). As for the human counterpart, in 2006 
Dolnikov et al. were the first to study the Ca2+-handling properties 
of hESC-CMs in detail (30). They reported that Ca2+ transients 
recorded from spontaneously beating or electrically stimulated 
hESC-CMs respond to neither caffeine nor ryanodine; hESC-CMs 
recorded as beating clusters also displayed a negative force-fre-
quency relationship that is different from adult CMs. Based on 
these observations, the authors concluded that hESC-CMs are im-
mature and do not express functional SRs, and that their contrac-
tions result from trans-sarcolemmal Ca2+ influx (rather than Ca2+ 
release from the SR). Due to the paucity of further hESC-CM data, 
we sought to help define the poorly known Ca2+-handling proper-
ties by recording and comparing Ca2+ transients from hESC-CMs 
and human fetal left ventricular (LV) CMs (16–18 weeks) (Fig. 
2A). In stark contrast to the previous study, we demonstrated the 
presence of functional SRs even in hESC-CMs that were younger 
(31) (18–24 vs. 55-day old post-differentiation of Dolnikov et al.). 
Upon electrical stimulation, hESC- and fetal LV-CMs generated 
similar Ca2+ transients. However, caffeine induced Ca2+ release in 
65% of fetal LV-CMs and only ∼40% of H1– and HES2-CMs. Rya-
© Schattauer 2010 Thrombosis and Haemostasis 104.1/2010
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Figure 2: Functional but immature 
Ca2+-handling of hESC-CMs as compared 
to FLV-CMs and ALV-CMs. A) Representative 
tracings caffeine-induced Ca2+ transients of 
HES2-, H1-, and FLV-CMs. B) % of caffeine-re-
sponsive and -insensitive cells. C) Expression of 
various Ca2+ handling proteins. β-actin was 
used as the loading control. D) Immunostaining 
of RyRs. Adapted from Liu et al. 2007. 
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nodine significantly reduced the electrically-evoked Ca2+ transient 
amplitudes and slowed the upstroke of caffeine-responsive HES2– 
and H1-CMs but NOT caffeine-insensitive cells; thapsigargin, a 
SERCA inhibitor, similarly reduced the amplitude and slowed the 
decay of only caffeine-responsive HES2– and H1-CMs (31). Thus, 
the discrepancy can be largely attributed to the newly identified 
caffeine-responsive population. NCX protein expression is highest 
in hESC-CMs, but intermediate and weakest in fetal and adult LV-
CMs, respectively. We later confirmed that the same trend is also 
seen at the functional level (32). Although highest in adult LV-
CMs, SERCA2a is already substantially and comparably expressed 
in H1-, HES2-, and fetal LV-CMs. RyR is expressed in hESC-CMs 
and fetal LV-CMs, but the organised pattern for adult LV-CMs is 
not observed (due to the lack of t-tubules in hESC-CMs). On the 
far end, the regulatory proteins junctin, triadin, and calsequestrin 
(CSQ) are expressed in adult LV-CMs but completely absent in 
hESC-CMs. Furthermore, hESC-CMs do not display t-tubules that 
are seen in normal adult human atrial and ventricular CMs (33) 
(Fig. 3). Consistent with the lack of t-tubules, the Ca2+ wavefront 
of hESC-CMs is U-shaped, suggesting inefficient CICR or time 
delay in activation of RyRs at the centre with faster and greater 
magnitude of Ca2+ transient increase at the periphery relative to 
the central part of the cells (33). Table 1 summarises some 
Ca2+-handling properties of hESC-, fetal and adult CMs. 
Ca2+ homeostasis is dependent on such Ca2+-handling proteins 
as ICa,L channels, RyR, SERCA and NCX. RyRs are arranged in large 
organised arrays (up to 200 nm in diameter with more than 100 
RyRs) at the junctions between the SR and sarcolemma (i.e. 
t-tubules) beneath ICa,L channels (34). These arrays constitute a 
large functional Ca2+ release complex. RyRs are also coupled to 
other proteins at the luminal SR surface such as triadin, junctin 
and calsequestrin (CSQ) (35). As the most abundant, high-capac-
ity but low-infinity Ca-binding protein in the SR, the cardiac iso-
form CSQ2 can store up to 20 mM Ca2+ while buffering the free SR 
[Ca2+] at ∼1 mM (36). This allows repetitive muscle contractions 
without run-down. CSQ2 also coordinates the rates of SR Ca2+ re-
lease and loading by modulating RyR activities. Indeed, the SR 
Ca2+ content affects the amount of Ca2+ released via CICR (37, 38). 
For a given ICa, L trigger, a high SR Ca2+ load enhances the open 
probability of RyRs while directly providing more Ca2+ available 
for release (39). By contrast, ICa can no longer cause CICR when the 
SR Ca2+ content is sufficiently low. Mechanistically, CSQ senses the 
levels of luminal Ca2+ and effects RyRs via triadin and junctin. For 
instance, when SR Ca2+ declines (e.g. during Ca2+ release), the in-
creased level of Ca2+-free CSQ deactivates RyRs by binding via tria-
din and junction; alternatively, SR Ca2+ reload (e.g. upon relax-
ation when CICR terminates) relieves the CSQ2-mediated in-
hibition of RyRs (36, 40). Thus, CSQ2 is an important determinant 
of the SR load. Interestingly, CSQ can activate purified RyRs in the 
absence of triadin and junction (41, 42). As mentioned, CSQ is 
completely absent in hESC-CMs. We hypothesised that gene 
transfer of CSQ in hESC-CMs suffices to induce functional im-
Figure 3: T-tubule imaging of a hESC-CM and a mature ventricular 
CM. Di-8-ANEPPS confocal microscopic images of a hESC-CM (A) did not 
show intracellular fluorescent spots like those in an adult guinea pig ven-
tricular CM (C) suggesting the absence of t-tubules. The absence of t-tubules 
in ESC-CMs was further confirmed by atomic force microscopy (AFM) im-
aging of an adult ventricular cardiomyocyte (D) showing regularly spaced 
pores in the sarcolemma that coincide with the Z-lines, while hESC-CM (B) 
surface showed comparatively smoother topology with no presence of in-
vaginations that are indicative of t-tubules. E) Electrically induced Ca2+ tran-
sient in hESC-CMs. Top: Time progression linescans of pseudo-colored tran-
sient increase in intracellular Ca2+ across the mid-plane of a hESC-CM 
showed a U-shaped wavefront. Bottom: Quantified Ca2+ transient of linesc-
ans of the top panel. Adapted from Lieu et al. 2009. 
provement of SR. Figure 4 shows that transduction of hESC-
CMs by the adenovirus Ad-CMV-CSQ-IRES-GFP (Ad-CSQ) sig-
nificantly increased the transient amplitude, upstroke velocity and 
decay in comparison to the Ad-CMV-GFP and Ad-CMV-CSQΔ-
IRES-GFP control groups. CSQΔ is a non-functional version of 
CSQ with 53–869bp of the coding sequence deleted (43). Ad-CSQ 
also increased the SR Ca2+ content (as tested by caffeine), without 
altering ICa, L, suggesting that the improved transient was not 
simply due to more Ca2+ influx for CICR. 
Immature electrophyshiological properties of 
hESC-CMs 
Adult LV CMs are normally electrically silent-yet-excitable upon 
stimulation. To assess the electrical maturity of ventricular hESC-
CMs, we investigated their ability to generate APs. The majority of 
ventricular hESC-CMs were spontaneously firing, exhibiting a 
high degree of automaticity. The remaining quiescent cells could 
elicit single APs upon stimulation, indicating that their excitability 
was intact. However, these silent-yet-excitable ventricular hESC-
CMs displayed a prominent “phase 4-like” depolarisation, a known 
substrate for delayed after depolarisation (DAD). Furthermore, 
their resting membrane potentials (RMPs) were significantly de-
polarised. Collectively, these immature electrical properties of 
hESC-CMs are signatures of arrhythmogenic, failing adult ven-
tricular CMs. Thus, strategies for facilitated maturation need to be 
developed. Building upon our series of cardiac automaticity 
studies (44–48), we first identified the lack of Kir2.1-encoded IK1 in 
hESC-CMs as the primary mechanistic contributor to the imma-
ture proarrhythmic electrophysiological properties. Forced Kir2.1 
expression alone sufficed to render the electrical phenotype indis-
tinguishable from that of primary adult ventricular cells. Based on 
these proof-of-concept data that the developmentally arrested 
Ca2+ and electrophysiological phenotypes of hESC-CMs can be 
rescued, we are currently developing a non-genetic, non-phar-
macologic method for reproducibly driving global maturation, by 
targeting the micro-environmental niches and other non-cell au-
tonomous means. 
Human iPSC-derived cardiomyocytes 
We have previously reported that both human ESCs and iPSCs ex-
press several specialised ion channel proteins that appear to regu-
late cell proliferation and cell cycle (49, 50). Using the same meth-
ods for hESCs, human iPSCs can likewise differentiate into CMs 
with cardiac-specific molecular, structural, electrophysiological 
and Ca2+-handling properties (51). The iPSC-derived CMs ex-
pressed cardiac-specific transcription factors and structural pro-
teins (22). Functional CMs with nodal-, atrial-, or ventricular-like 
Table 1: Summary of differences. H1- and 
HES2-CMs have comparable trends and are 
collectively referred to as hESC-CMs.
 hESC-CMs Fetal LVCMs Adult LVCMs 
Expression levels of 
Ca2+-handling proteins  
 
RyR ++ ++ ++++ 
SERCA +++ +++ ++++ 
Phospholamban - ++ ++++ 
CSQ/Tdn/Jtn - + ++++ 
Calreticulin ++++ ++++ + 
NCX +++ ++++ + 
Ca2+ transient 
properties 
Basal [Ca2+]i ++ +++ ++++ 
Amplitude ++ ++ ++++ 
Decay  ++ ++ ++++ 
Upstroke  ++ ++ ++++
35 Kong et al. Translational potential of human ESC and iPSC
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Figure 4: Effect of CSQ overexpression on hESC-CMs. A) Representative 
electrically-induced Ca2+ transient tracings for Ad-GFP (n=12) and Ad-CSQ 
(n=29) transduced hESC-CMs. B) Bar graphs of amplitude.* P < 0.05, 
** P < 0.01. Adapted from Liu et al. 2009. 
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electrophysiological phenotypes have also been observed (51). 
Multielectrode array recordings established the development of a 
functional syncytium with stable pacemaker activity and action 
potential propagation. Positive and negative chronotropic re-
sponses were induced by application of isoproterenol and carba-
mylcholine, respectively (22). Like hESC-CMs, iPSC-CMs also dis-
play immature Ca2+-handling properties with smaller transient 
amplitude and slowed kinetics (unpublished). Depending on the 
method and conditions of reprogramming, however, some iPSC-
CMs appear to be more resistant to maturation methods that work 
effectively for hESC-CMs. In addition to clinical applications, the 
ability to generate patient-specific hiPSC-CMs also provides an 
opportunity to develop novel in vitro models of cardiac disorders. 
Indeed, these in vitro models could serve as a platform for investi-
gating arrhythmia mechanisms and for predicting efficacy of phar-
macological therapies. 
Electronic pacemakers for heart rhythm  
disorders 
Normal rhythms originate in the sino-atrial node (SAN), a special-
ised cardiac tissue consisting of only a few thousands pacemaker 
cells (52, 53). Malfunction of cardiac pacemaker cells leads to 
rhythm generation disorders. Traditional treatments require phar-
macological intervention and/or implantation of electronic pace-
makers. While such therapy is effective, it is also associated with 
significant risks (e.g. infection, haemorrhage, lung collapse and 
death) and expenses (>600,000 cardiac pacemakers are implanted 
annually worldwide). Other disadvantages include limited battery 
life (replaced every 5–10 years), permanent implantation of ca-
theters, and lack of autonomic neurohumoral responses. As for 
paediatric patients with conditions such as symptomatic bradyc-
ardias, bradycardia-dependent ventricular arrhythmias and other 
postoperative arrhythmias that require electronic pacemakers for 
life-sustaining rhythms, several considerations can complicate 
their management (54–58). For instance, somatic growth may re-
sult in lead tension and thereby increase the risk of lead dislodging 
and fracturing that are fairly common in active young patients. 
The placement of an electronic system could also be hindered by 
congenital heart defects and structural abnormalities. 
Unlike rhythmically AP-firing pacemaker cells, adult atrial and 
ventricular muscle cells are normally electrically silent unless they 
get stimulated by signals transmitted from neighbouring cells that 
originate from the SAN. This quiescent nature of cardiac muscle 
CMs is due to the absence of If and the intense expression of IK1 
(a.k.a. the inward-rectifier K+ current), encoded by the Kir2 gene 
family, which stabilises a negative resting membrane potential 
(RMP ∼-80 mV). Given the limitations of electronic pacemakers, 
several gene- and cell-based approaches have been explored to 
confer upon normally-quiescent cardiac muscle cells the ability to 
intrinsically fire APs similar to genuine nodal pacemaker cells as 
potential biological alternatives or supplements to devices. In ad-
dition to the translational potential, these studies also shed mech-
anistic insights into cardiac automaticity. Miake et al. demon-
strated that genetic suppression of IK1 in normally-silent ventricu-
lar myocytes by >80% can cause spontaneous firing activity in a bi-
nary “on-and-off” fashion (59). The induced frequency is only a 
third of normal, and as such not suitable for acting as a reliable bio-
logical pacemaker. Alternatively, we (44, 48, 60) and others (61) 
have chosen to employ a genuine pacemaker gene product – the 
HCN channels. Since the four HCN isoforms co-assemble to form 
heteromultimeric channels, the molecular identity of endogenous 
If is complex and therefore difficult to reproduce via genetic ex-
pression of a single HCN isoform. Furthermore, subunit inter-
actions of HCN are poorly defined. Indeed, overexpression of WT 
HCN1 (48) or HCN2 (62) channels alone in quiescent ventricular 
CMs is insufficient to cause oscillations. We overcame this hurdle 
by protein engineering of HCN to create a single construct that 
mimics native nodal If (63–65), thereby enabling us to sub-
sequently construct a functional bioartificial SAN (bio-SAN) in a 
large animal (swine) model of sick sinus syndrome (SSS) (48, 60). 
Side-by-side comparison in this SSS porcine model shows that bio-
SAN significantly reduces the dependence on device-supported 
pacing by electronic pacemaker from ∼85% to ∼15% in the same 
animal after receiving our treatment.  
Alternatively, pluripotent human embryonic stem cells (hESCs) 
can be differentiated into pacemaker-like derivatives for transplan-
tation to recreate an in vivo pacemaker (8, 66). To create biological 
pacemakers, human mesenchymal stem cells (hMSCs) pre-trans-
fected with HCN2 channels have also been employed as a delivery 
vehicle for introducing If into neighboring CMs via gap junction-
mediated coupling (67, 68). The stability of such coupling between 
non-cardiac cells and the myocardium needs to be considered and 
requires further investigations. Along the same line, ventricular 
myocytes have been converted into pacemaker-like heterokaryons 
via chemically-induced fusion with fibroblasts transduced to ex-
press HCN1 channels (69). When injected into the guinea pig left 
ventricle (LV), electrocardiography (ECG) confirmed ectopic 
rhythms. Previous studies have indicated that similar hetero-
karyons can remain stable for several months (70–72).  
Myocardial repair 
Myocardial infarction remains the major worldwide cardiovascu-
lar disorder in humans. Immediately after a heart attack, oxygen 
starvation of myocardial tissues leads to cell death, and in the ab-
sence of immediate thrombolytic treatment of the blocked coron-
ary artery, the damage is often irreversible and the heart is perma-
nently impaired. Despite significant improvements in the manage-
ment of most cardiovascular disorders, sudden cardiac death 
(SCD) due to ventricular arrhythmias remains a leading cause of 
morbidity and mortality in the industrialised world, claiming well 
over 300,000 lives annually in the United States alone. Current 
treatment options for arrhythmias in patients with heart failure 
have been especially disappointing, in many cases promoting 
rather than preventing SCD. Longer term, the remaining CMs hy-
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pertrophy in an attempt to meet the functional demands, while 
cardiac fibroblasts secrete collagen and other extracellular matrix 
proteins during scar formation, which may further impair ven-
tricular function. Indeed, myocardial tissue recovery is particularly 
limited by its intrinsic inability to regenerate. Palliative interven-
tions to treat damaged heart muscle include changes in life-style, 
medications that reduce functional requirements or limit certain 
aspects of remodelling, or surgical interventions that improve car-
diac function. In severe cases, transplantation is the only option, 
and today’s most urgent problem in transplantation is the lack of 
suitable donor organs and tissues. As mentioned, damaged myoc-
ardium could be treated by cell transplantation/replacement ther-
apy. The lack of effective and safe therapeutic options for heart fail-
ure patients, coupled with a growing understanding of cardiac re-
generative processes and stem cell biology have led to the develop-
ment of various cell-based therapies that have shown significant 
promises in at least partially restoring cardiac function by reducing 
infarct size. Potential and actual sources of cells or tissues are self 
(autologous), same species (allogeneic), different species (xeno-
graphic), primary or immortalised cell lines, and embryonic or 
adult stem cell-derived donor cells.  
Pathophysiological remodeling of cardiac function occurs at 
multiple levels, spanning the spectrum from molecular and sub-
cellular changes to those occurring at the organ-system levels. 
Complex alterations in a host of ion channels, Ca2+-cycling pro-
teins, and gap junction-related molecules modulates key electro-
physiological properties, predisposing to arrhythmias caused by 
enhanced automaticity, triggered activity, and reentry. Heart fail-
ure-induced ion channel dysfunction prolongs the AP, increases 
spatiotemporal gradients of repolarisation, promotes the 
formation of arrhythmogenic triggers and results in conduction 
abnormalities. Cell-based therapies can significantly improve LV 
function. As such, these therapies may activate complex signalling 
processes that reverse-remodel the failing heart, and therefore pre-
vent the incidence of arrhythmias. On the other hand, cell-based 
therapies might also alter the RMP, produce abnormal triggers, 
promote electrical heterogeneities, modulate conduction, and fa-
vour reentrant excitation. As already described, of major concern is 
the fact that hESC- and iPSC-CMs display a range of functional 
and structural properties that are remarkably similar to those of 
immature or failing heart cells. These properties along with a de-
tailed investigation of their electrophysiological consequences 
require careful investigation before their clinical efficacy can be 
further assessed. 
Conclusion 
The availability of hESC and iPSC and their successful differenti-
ation into genuine human heart cells have enabled clinicians and 
scientists to gain insights into the early development of the human 
heart as well as to pursue to the revolutionary paradigm of heart 
regeneration. However, hESC- and iPSC-derived CMs appear to be 
both structurally and functionally immature. One of the most im-
portant factors to consider before any potential benefits of hESC-
CMs are clinically assessed would be to ensure their safety. Fur-
thermore, the successful use of derived CMs as human heart dis-
ease models and cardiotoxicity screening tools depends on their 
ability to recapitulate the properties of their adult counterparts. 
Further studies are required to promote their maturation. When 
combined with other advances in driven differentiation and car-
diovascular progenitor identification (19–21), the approaches can 
facilitate the translation of hESC/iPSCs into clinical and other ap-
plications.  
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